211 related articles for article (PubMed ID: 33781630)
1. Non-Invasive Prenatal Fetal Blood Group Genotype and Its Application in the Management of Hemolytic Disease of Fetus and Newborn: Systematic Review and Meta-Analysis.
Alshehri AA; Jackson DE
Transfus Med Rev; 2021 Apr; 35(2):85-94. PubMed ID: 33781630
[TBL] [Abstract][Full Text] [Related]
2. Noninvasive Fetal RhD Blood Group Genotyping: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2020; 20(15):1-160. PubMed ID: 33240456
[TBL] [Abstract][Full Text] [Related]
3. Non-invasive prenatal testing for management of haemolytic disease of the fetus and newborn induced by maternal alloimmunisation.
Hyland CA; O'Brien H; Flower RL; Gardener GJ
Transfus Apher Sci; 2020 Oct; 59(5):102947. PubMed ID: 33115620
[TBL] [Abstract][Full Text] [Related]
4. High-throughput non-invasive prenatal testing for fetal rhesus D status in RhD-negative women not known to be sensitised to the RhD antigen: a systematic review and economic evaluation.
Saramago P; Yang H; Llewellyn A; Walker R; Harden M; Palmer S; Griffin S; Simmonds M
Health Technol Assess; 2018 Mar; 22(13):1-172. PubMed ID: 29580376
[TBL] [Abstract][Full Text] [Related]
5. High-throughput, non-invasive prenatal testing for fetal rhesus D status in RhD-negative women: a systematic review and meta-analysis.
Yang H; Llewellyn A; Walker R; Harden M; Saramago P; Griffin S; Simmonds M
BMC Med; 2019 Feb; 17(1):37. PubMed ID: 30760268
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic performance of the noninvasive prenatal FetoGnost RhD assay for the prediction of the fetal RhD blood group status.
Legler TJ; Lührig S; Korschineck I; Schwartz D
Arch Gynecol Obstet; 2021 Nov; 304(5):1191-1196. PubMed ID: 33835210
[TBL] [Abstract][Full Text] [Related]
7. Routine administration of Anti-D: the ethical case for offering pregnant women fetal RHD genotyping and a review of policy and practice.
Kent J; Farrell AM; Soothill P
BMC Pregnancy Childbirth; 2014 Feb; 14():87. PubMed ID: 24568571
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of noninvasive fetal RhD blood group genotyping in nonalloimmunized and alloimmunized pregnancies.
Gajic-Veljanoski O; Li C; Schaink AK; Guo J; Shehata N; Charames GS; de Vrijer B; Clarke G; Pechlivanoglou P; Okun N; Kandel R; Dooley J; Higgins C; Ng V; Sikich N
Transfusion; 2022 May; 62(5):1089-1102. PubMed ID: 35170037
[TBL] [Abstract][Full Text] [Related]
9. Antenatal
Clausen FB
Immunohematology; 2024 Apr; 40(1):15-27. PubMed ID: 38739027
[TBL] [Abstract][Full Text] [Related]
10. The role of non-invasive prenatal testing (NIPT) for fetal blood group typing in Australia.
Ginige S; Daly J; Hyland C; Powley T; O'Brien H; Moreno AM; Gardener G; Flower R
Aust N Z J Obstet Gynaecol; 2022 Feb; 62(1):33-36. PubMed ID: 34661280
[TBL] [Abstract][Full Text] [Related]
11. Validation of a non-invasive prenatal test for fetal RhD, C, c, E, K and Fy
Alford B; Landry BP; Hou S; Bower X; Bueno AM; Chen D; Husic B; Cantonwine DE; McElrath TF; Carozza JA; Wynn J; Hoskovec J; Gray KJ
Sci Rep; 2023 Aug; 13(1):12786. PubMed ID: 37550335
[TBL] [Abstract][Full Text] [Related]
12. High-throughput, non-invasive prenatal testing for fetal Rhesus D genotype to guide antenatal prophylaxis with anti-D immunoglobulin: a cost-effectiveness analysis.
Saramago P; Yang H; Llewellyn A; Palmer S; Simmonds M; Griffin S
BJOG; 2018 Oct; 125(11):1414-1422. PubMed ID: 29415334
[TBL] [Abstract][Full Text] [Related]
13. Noninvasive fetal RhD genotyping from maternal blood.
Kolialexi A; Tounta G; Mavrou A
Expert Rev Mol Diagn; 2010 Apr; 10(3):285-96. PubMed ID: 20370586
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic accuracy of noninvasive fetal Rh genotyping from maternal blood--a meta-analysis.
Geifman-Holtzman O; Grotegut CA; Gaughan JP
Am J Obstet Gynecol; 2006 Oct; 195(4):1163-73. PubMed ID: 17000250
[TBL] [Abstract][Full Text] [Related]
15. Determination of fetal RHD type in plasma of RhD negative pregnant women.
Sørensen K; Kjeldsen-Kragh J; Husby H; Akkök ÇA
Scand J Clin Lab Invest; 2018 Sep; 78(5):411-416. PubMed ID: 29869532
[TBL] [Abstract][Full Text] [Related]
16. Hemolytic disease of the fetus and newborn in the molecular era.
Fasano RM
Semin Fetal Neonatal Med; 2016 Feb; 21(1):28-34. PubMed ID: 26589360
[TBL] [Abstract][Full Text] [Related]
17. Screening of RHD fetal genotype in RhD negative women.
Kratochvílová T; Böhmová J; Durdová V; Vodička R; Holusková I; Langová K; Lubušký M
Ceska Gynekol; 2020; 85(3):156-163. PubMed ID: 33562966
[TBL] [Abstract][Full Text] [Related]
18. Hemolytic Disease of the Fetus and Newborn: Modern Practice and Future Investigations.
Hendrickson JE; Delaney M
Transfus Med Rev; 2016 Oct; 30(4):159-64. PubMed ID: 27397673
[TBL] [Abstract][Full Text] [Related]
19. Noninvasive Fetal RhD Blood Group Genotyping: A Systematic Review of Economic Evaluations.
Gajic-Veljanoski O; Li C; Schaink AK; Guo J; Higgins C; Shehata N; Okun N; de Vrijer B; Pechlivanoglou P; Ng V; Sikich N
J Obstet Gynaecol Can; 2021 Dec; 43(12):1416-1425.e5. PubMed ID: 34390866
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
